BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 32139220)

  • 21. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
    Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Tunehag KR; Thomas CD; Franchi F; Rossi JS; Keeley EC; Anderson RD; Beitelshees AL; Duarte JD; Gong Y; Kerensky RA; McDonough CW; Nguyen AB; Ortega-Paz L; Venkatesh S; Wang Y; Johnson JA; Winterstein AG; Stouffer GA; Angiolillo DJ; Cavallari LH; Lee CR
    J Am Heart Assoc; 2024 Jun; 13(12):e033791. PubMed ID: 38874073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction.
    Flierl U; Zauner F; Sieweke JT; Berliner C; Napp LC; Tillmanns J; Bauersachs J; Schäfer A
    Thromb Haemost; 2017 Jan; 117(1):99-104. PubMed ID: 27734075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
    Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
    Novkovic M; Matic D; Kusic-Tisma J; Antonijevic N; Radojkovic D; Rakicevic L
    Eur J Clin Pharmacol; 2018 Apr; 74(4):443-451. PubMed ID: 29260275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bedside testing of CYP2C19 vs. conventional clopidogrel treatment to guide antiplatelet therapy in ST-segment elevation myocardial infarction patients.
    Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al-Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Loza BL; Claassens DMF; Asselbergs FW; Al-Ali AK
    Int J Cardiol; 2021 Nov; 343():15-20. PubMed ID: 34506827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
    Doll JA; Neely ML; Roe MT; Armstrong PW; White HD; Prabhakaran D; Winters KJ; Duvvuru S; Sundseth SS; Jakubowski JA; Gurbel PA; Bhatt DL; Ohman EM; Fox KAA;
    J Am Coll Cardiol; 2016 Mar; 67(8):936-947. PubMed ID: 26916483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clopidogrel Pharmacogenetics.
    Pereira NL; Rihal CS; So DYF; Rosenberg Y; Lennon RJ; Mathew V; Goodman SG; Weinshilboum RM; Wang L; Baudhuin LM; Lerman A; Hasan A; Iturriaga E; Fu YP; Geller N; Bailey K; Farkouh ME
    Circ Cardiovasc Interv; 2019 Apr; 12(4):e007811. PubMed ID: 30998396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized Comparison of Intensified and Standard P2Y
    Mehilli J; Baquet M; Hochholzer W; Mayer K; Tesche C; Aradi D; Xu Y; Thienel M; Gschwendtner S; Zadrozny M; Jochheim D; Sibbing D; Schüpke S; Mansmann U; Hoffmann E; Kastrati A; Neumann FJ; Massberg S
    Circ Cardiovasc Interv; 2020 Jun; 13(6):e008649. PubMed ID: 32527192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.
    You J; Li H; Guo W; Li J; Gao L; Wang Y; Geng L; Wang X; Wan Q; Zhang Q
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():598-605. PubMed ID: 31957972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study design and rationale for Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective percutaneous coronary intervention patients (ONSIDE TEST): a prospective, open-label, randomised parallel-group multicentre trial (NCT01930773).
    Kołtowski Ł; Aradi D; Huczek Z; Tomaniak M; Sibbing D; Filipiak KJ; Kochman J; Balsam P; Opolski G
    Kardiol Pol; 2016; 74(4):372-9. PubMed ID: 26365936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
    Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
    Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
    Máchal J; Hlinomaz O
    Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
    Palmerini T; Calabrò P; Piscione F; De Servi S; Cattaneo M; Maffeo D; Toso A; Bartorelli A; Palmieri C; De Carlo M; Capodanno D; Barozzi C; Tomasi L; Della Riva D; Mariani A; Taglieri N; Reggiani LB; Bianchi R; De Rosa R; Mariani M; Podda G; Généreux P; Stone GW; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Oct; 7(10):1117-27. PubMed ID: 25240538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clopidogrel pharmacogenetics: associations between genotype and stent thrombosis risk in patients with stent placement.
    Ferrari M; Tozzi M; Marino F; Tarallo A; Riva F; Mirabile M; Castelli P; Cosentino M
    J Cardiovasc Med (Hagerstown); 2019 Jan; 20(1):46-48. PubMed ID: 30531616
    [No Abstract]   [Full Text] [Related]  

  • 38. Switching from ticagrelor to clopidogrel in patients with ST-segment elevation myocardial infarction undergoing successful percutaneous coronary intervention in real-world China: Occurrences, reasons, and long-term clinical outcomes.
    Li XY; Su GH; Wang GX; Hu HY; Fan CJ
    Clin Cardiol; 2018 Nov; 41(11):1446-1454. PubMed ID: 30225843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
    Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
    Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of body mass index on clinical outcome among elderly patients with acute coronary syndrome treated with percutaneous coronary intervention: Insights from the ELDERLY ACS 2 trial.
    De Luca G; Verdoia M; Savonitto S; Ferri LA; Piatti L; Grosseto D; Morici N; Bossi I; Sganzerla P; Tortorella G; Cacucci M; Ferrario M; Murena E; Sibilio G; Tondi S; Toso A; Bongioanni S; Ravera A; Corrada E; Mariani M; Di Ascenzo L; Petronio AS; Cavallini C; Vitrella G; Antonicelli R; Rogacka R; De Servi S;
    Nutr Metab Cardiovasc Dis; 2020 May; 30(5):730-737. PubMed ID: 32127336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.